



Comprehensive Registry- Based Surveillance



Danica Marinac-Dabic, MD, PhD
Director, Division of Epidemiology

Wednesday, April 27, 2016



What is it?

FDA Investments in the Foundation of the National System

MDEpiNet Registry Task Force: Birth of Strategically Coordinated Registry Network (CRN) Concept

Paradigm Shift: NEMDS and Comprehensive Registry-Based Surveillance

Moving Forward

What is it?


- Surveillance Arm of Comprehensive Evidence Evaluation
- Registry-Based (registry, consortia, CRN)
- National/International
- Embedded in the Health Care System
- Shared Responsibilities
- Mandated – vision to evolve into non-mandated

Changing Evidentiary Paradigm for Development and Evaluation of Medical Devices



From:
One-directional Evidence Stream



To:
Multidirectional Evidence Streams throughout the TPLC of device and its iterations



Foundational Work: 2010-2016



FDA Investments 2011-2015

UDI Established a Unique Device Identification (UDI) System

50 Completed or engaged in over 50 projects, including the creation of new RWE data sources, demonstration of proof of concept for use of RWE, development and use of advanced analytics

\$20,000,000 Invested over \$20 million to stand up MDEpiNet

MDEpiNet Efforts

Infrastructure

Registry Development
National/International Consortia
Development
Electronic Device Data Capture (UDI)
Task Force -Coordinated Registry Networks
PASSION Initiative

Active Surveillance
Distributed Data Analysis
Evidence Synthesis
Claims Validation
Linkage with other Data Sources
Big Data Analytics


Methods

Patient Engagement


Augmenting Registries with PROs and Explant
Analysis for Precision Medicine
Assessing Minimally Important Difference
(MID) for orthopedics implants
Patient and Family Engagement Committee
Patient-led Device/Disease Specific Round
Table

National Registry Task Force

- Strategically Coordinated Registry Network (CRN)
- Registry Task Force proposed priority device areas in need of coordinated registry networks (registries linked to other data sources)
- PASSION initiative builds foundation of CRNs



Paradigm Shift



Early Successes

National registries are being leveraged for:

- 15 Post-Approval studies
- 1 Continued Access study
- 1 labeling extension study
- 7 Postmarket Surveillance Studies (522)


International Registries are being leveraged for:

- 3 post-approval studies

Active review/analysis of data (starting early 2016)

- Example: American College of Cardiology (ACC) will share data with FDA quarterly for review
- Separate studies are no longer required, providing additional value

Impact: Shifts in Cardiovascular Device Post-Approval Studies Since 2010



Number of expensive studies is decreasing; replaced by cheaper studies.

Data as of November 30, 2015.

Trans-catheter Heart Valve Approvals and TVT Registry

N = 10 Post-Approval Requirements within Registry

Sapien
**inoperable
patients**
11-02-11

TVT Registry
Launched
12-2011

Sapien
**operative
patients**
10-19-12

MitraClip
**prohibited
risk
patients**
10-24-13

CoreValve
**extreme risk or
inoperable
patients**
01-17-14

CoreValve
**high or greater
risk patients**
06-12-14

Sapien XT
**high or greater
risk patients**
06-16-14

CoreValve
**high or greater risk patients,
added failure of mechanical
heart valve**
03-30-15

Sapien 3
high or greater risk patients
06-17-15

Sapien 3
**high or greater risk
patients, added failure of
mechanical heart valve**
10-09-15

2011

2012


2013

2014

2015

2016

Impact: Registry Data Reduces Premarket Review Time!



Moving Forward

- Advance CRN infrastructure via PASSION Initiative
 - More efficient fit for purpose (real and virtual) registries
 - Link registries (national and international) with longitudinal data (claims, EHR, PCORNET)
- Enable use of innovative methodological approaches for studies
 - Registry-derived comparison groups, EHR-driven comparison groups, big data analytics
 - Nesting new clinical trials in registries (e.g., Safe STEMI for Seniors)
- Robust regulatory apparatus that utilizes RWE to streamline device evaluation, ensures nearly real time surveillance and support innovation

Thank you!



Danica.marinac-dabic@fda.hhs.gov



@mdepinet



www.mdepinet.org